CONTEXT: Dengue is considered to rank fifth among the most costly diseases in terms of public costs, since its annual burden is 750 thousand DALYs¹¯². Panama shows an endemic pattern of cyclical peaks every 3 to 5 years (2005, 2009 and 2014). According to the epidemiological surveillance data, in 2005, Panama experienced one of the largest dengue epidemic; 5,489 dengue cases, 7 hemorrhagic cases and 5 deaths have been confirmed. Its incidence rate was 170 cases per 100,000 inhabitants. OBJECTIVES: Purpose of this study is to assess in different scenarios (routine with or without catch-up cohorts) the impact of a tetravalent dengue vaccine in Panama through a cost-effectiveness analysis, estimating the burden of the disease based on DALY (Disability Adjusted Life Years). METHODS: A dynamic, compartmental and deterministic, transmission model of the disease was used to estimate the burden of the disease and related costs for several vaccination scenarios with dengue vaccine compared with no vaccination (NV) over 10 years (2017-2026). RESULTS: By using as a reference the WHO criterion for assessing health interventions—from the social perspective, considering indirect effect and under-reporting— the maximum price per dose for the intervention to be cost-effective is estimated in U$51.4 for a vaccination in the nine year-old risk population (R9), U$74.5 for a vaccination in the nine to fifteen year-old risk population (R9+6). Additionally, when the health impact is analyzed in terms of percentage reduction of the total dengue cases by scenario, the results are the following: -26% (R9), -59% (R9+6). CONCLUSIONS: These results allow the determination of the maximum price for a cost-effective implementation and show that the wider the immunization schedule, the greater the effect on economy and health.